Sistema de Salut de Catalunya
[Masana L, Rodríguez-Borjabad C] CIBERDEM, Universitat Rovira i Virgili, LIPIDCAS, University Hospital Sant Joan IISPV, Reus, Spain. [Correig E] Universitat Rovira i Virgili, Statistics Department, Institut Investigació Sanitaria Pere Virgili, Reus, Spain. [Anoro E] LIPIDCAS, Pius Hospital Valls, Valls, Spain. [Arroyo JA] Lipid Unit, University Hospital Santa Creu i Sant Pau, Barcelona Autonomous University, Barcelona, Spain. [Jericó C] Lipid Unit, Hospital Moises Broggi, Consorci Sanitari Integral, Sant Joan Despí, Spain. [Pedragosa A] Unitat de lípids, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain
Consorci Sanitari de Terrassa
2023-06-19T12:01:01Z
2023-06-19T12:01:01Z
2022-02-16
COVID-19; Cardiovascular risk; Mortality
COVID 19; Risc cardiovascular; Mortalitat
COVID-19; Riesgo cardiovascular; Mortalidad
Aim: Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-hospital mortality. Methods and results: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk. Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients [1234 men, 923 women; age: 67 y/o (IQR 54-78)] admitted to the hospital were retrieved from the clinical records in anonymized manner. Three hundred and fifty-three deaths occurred. Five hundred and eighty-one patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on ST than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: P = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared with the GM non-statin group (17.4%; P = 0.045). The Cox model applied to the CSH function [HR = 0.58(CI: 0.39-0.89); P = 0.01] and the competing-risks FG model [HR = 0.60 (CI: 0.39-0.92); P = 0.02] suggest that statins are associated with reduced COVID-19-related mortality. Conclusions: A lower SARS-CoV-2 infection-related mortality was observed in patients treated with ST prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19.
Article
Published version
English
Estatines (Medicaments cardiovasculars); COVID-19 (Malaltia); Hospitals - Pacients; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents::Anticholesteremic Agents::Hydroxymethylglutaryl-CoA Reductase Inhibitors; HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Services::Patient Care::Hospitalization; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antimetabolitos::hipolipemiantes::anticolesterolemiantes::inhibidores de las hidroximetilglutaril-CoA reductasas; ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::asistencia al paciente::hospitalización
Oxford University Press
European Heart Journal - Cardiovascular Pharmacotherapy;8(2)
https://doi.org/10.1093/ehjcvp/pvaa128
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - CST [139]
Articles científics - HVH [3437]
